Loading...
XSHE
300966
Market cap494mUSD
Jul 09, Last price  
29.10CNY
1D
-1.89%
1Q
37.01%
IPO
-30.78%
Name

Hubei Goto Biopharm Co Ltd

Chart & Performance

D1W1MN
XSHE:300966 chart
P/E
P/S
5.53
EPS
Div Yield, %
0.05%
Shrs. gr., 5y
1.65%
Rev. gr., 5y
0.51%
Revenues
606m
+12.97%
333,692,153437,301,669464,801,920468,117,263590,885,338590,885,338604,571,473604,571,472566,399,208536,595,591606,178,267
Net income
-73m
L+165.88%
47,438,68470,677,87772,996,36253,288,52578,330,63578,330,64240,205,16040,205,16123,005,020-27,591,125-73,359,121
CFO
41m
P
008,502,36613,474,98758,004,300068,132,538-20,588,44741,036,390
Dividend
Jun 12, 20240.016 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Hubei Goto Biopharm Co.,Ltd. is a Chinese enterprise specializing in the manufacture and distribution of active pharmaceutical ingredients (APIs) and intermediate compounds for steroid hormones. Its product line features essential starting materials such as 9a-hydroxy-4-androstenedione (9a-OHAD), bisnoralcohol (BA), sitolactone, 1,4-androstadienedione (ADD), and 4-androstenedione (4-AD). The company also provides a variety of intermediates, including those for estrogens, progesterone, non-steroidal substances, various other hormones, and corticosteroids. Furthermore, Hubei Goto Biopharm supplies additional raw materials for the pharmaceutical industry. The firm was established in Yicheng, China, in 2006.
IPO date
Apr 09, 2021
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT